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Abstract
Death certificates are used to classify cause of death for studies of cancer survival and mortality.
Using data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results
program, we evaluated cause of death (site-specific, cancer cause-specific, or other cause of death)
for 229,181 patients with distant stage disease during 1994–2003 who died by 2005. Agreement
between coded cause of death and initial diagnosis was 85% in patients with only one primary and
64% in patients with more than one primary. Our findings support the usefulness of site and
cancer cause-specific causes of death reported on the death certificate for distant stage patients
with a single cancer.
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INTRODUCTION
Cancer-specific and cancer site-specific survival and mortality are important outcomes for
tracking trends in population health and evaluating the impact of cancer control
interventions, including screening programs and cancer therapies (1–8). In addition, cancer
cause-specific and site-specific survival and mortality are frequently used as outcome
measures when evaluating the influence of patients’ socioeconomic status and clinical
characteristics, and provider and hospital characteristics on cancer care. An evaluation of
cause-specific survival and mortality requires reliable information on the cause of patients’
death. However, an examination of medical records to determine the cause of death is not
practical in large cohorts because of the expense and time required for accurate
ascertainment. Cause of death as obtained from the death certificate is frequently the only
feasible option when using cancer registry databases, large administrative datasets, or large
cohorts.
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Validation studies have reported conflicting findings on the reliability of the cause of death
from the death certificate, raising concerns about the utility of death certificate data to
measure death due to cancer (9–12) and death due to other causes (13, 14). Despite these
concerns, death certificate data are used in vital statistics and studies of site-specific and
cancer cause-specific survival and mortality. The purpose of this study is to inform the use
of the cause of death on death certificates in studies of survival and mortality by examining
the cause, cause-specific and site-specific causes of death in a population likely to die of
cancer, namely patients with distant stage disease at diagnosis.
METHODS
Data sources and sample population
We used data from the National Cancer Institute’s Surveillance, Epidemiology, and End
Results (SEER) program which includes 17 geographic areas, currently representing
approximately 26% of the United States (15). The SEER registries collect detailed
information on all incident cancers, including cancer site, stage, month and year of
diagnosis, and patient demographics. In addition, the SEER registries conduct follow-up to
determine vital status by using various methods such as contact with treating physicians,
links to state’s department of motor vehicles records, links to state’s vital records, searches
of state’s voter registrations, and links to the National Death Index. For patients who have
died, the registry data include the month, year, and underlying cause of death reported on the
death certificate.
We identified patients diagnosed with cancer of the breast (females only), colon/rectum,
stomach, head/neck, liver, lung, melanoma of the skin, ovary, pancreas, prostate, or uterus
using SEER*Stat (version 6.4.4). The SEER program collects information on the extent of
disease which is used to define SEER localized, regional, and distant historic stages. We
restricted the sample to patients diagnosed with SEER historic stage distant disease because
this definition does not change over time (16). We selected these sites because these patients
were likely to die from cancer than other causes. The most recent five-year relative survival
rates for the vast majority of these distant stage cancers were less than 25% (17). We
identified 231,613 patients diagnosed with distant stage disease at age 20 or older between
1994 and 2003, who had died by December 31, 2005. We excluded patients whose cancer
was first reported at autopsy or on the death certificate (n = 1,432). The final study sample
included 229,181 patients.
MEASURES
All measures used in the analysis were obtained from the SEER data. SEER obtains
underlying cause of death data from death certificates that are coded by the state health
department or state vital records in each SEER region. These death certificates are provided
by the states to the National Death Index. For each of the 11 cancer sites, deaths were
initially classified into three groups: “site-specific” (e.g., patients with a colorectal cancer
diagnosis and colorectal cancer cause of death), “cancer cause-specific, excluding site-
specific” (e.g., colorectal cancer diagnosis with a different cancer reported as the cause of
death), and “other cause of death” (e.g., tuberculosis, cerebrovascular disease, unknown
cause of death). Patients were also categorized as having “one primary only” or “more than
one primary.” In patients with more than one primary cancer, we reported the incident
cancer, which was required to be diagnosed at distant stage for cohort entry. Subsequent
cancer diagnoses were not restricted by stage.
Because this is a descriptive study, we were interested in examining variation in reported
cause of death by age at diagnosis (20–49, 50–64, 65–74, 75–84, and 85+), race/ethnicity
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(non-Hispanic white, non-Hispanic black, Hispanic, other), sex, and time from diagnosis to
death. To determine whether time between diagnosis and death influences the reported cause
of death, we categorized the period as 0–11, 12–23, 24–35, and 36–47 months between
diagnosis and death. In these analyses, we reported the percentage of diagnosed cancers with
“site-specific” and “cancer cause-specific” causes of death coded on the death certificate.
For each of the 11 cancer sites, we initially calculated the percentage of patient deaths that
were recorded on the death certificate as site-specific, cancer cause-specific, excluding site-
specific, or other cause of death. Because attributing the specific cause of death to patients
with more than one cancer diagnosis is difficult, we stratified patients with only one primary
cancer and those with more than one primary cancer. Following this initial assessment, we
focused on patients with only a single primary cancer. For these patients, we evaluated the
cause of death in two ways: site specific and cancer cause-specific causes of deaths. We
used chi-square (χ2) statistics to compare the percentage of all patient deaths reported on
death certificates that were attributable to each of the 11 cancer sites by demographic
characteristics or time since diagnosis. All statistical tests were two-sided and p-values are
reported.
RESULTS
Table 1 shows the distribution of the cause of death as reported on the death certificates by
cancer site. Of the 229,181 patients included in our analysis, 192,538 (84%) reportedly died
from the same site-specific cancer as their incident diagnosis in SEER. An additional 8%
were reported to have died of another cancer. Less than 9% of the sample had a cause of
death listed as other than cancer. Among patients with only one primary cancer recorded,
there was substantial agreement between incident cancer site diagnosis and reported cause of
death. For patients with a single primary diagnosis, the percentage of deaths attributable to
site-specific cancers exceeded 80% for lung (87%), pancreatic (87%), breast (85%), and
ovarian (85%) cancers. The poorest agreement was for patients with head and neck (58%),
liver (71%), and uterine (72%) cancers. For patients with only one cancer diagnosis, the
cause of death was recorded as cancer (either site-specific or cancer cause-specific,
excluding site-specific) in at least 85% of all cases, for 9 of the 11 cancer sites, included in
our analysis. The exceptions were for prostate (78%) and head and neck (84%) cancer.
When the “cancer cause-specific, excluding site-specific” category represented more than
10% of all deaths and the patient was diagnosed with only one primary cancer, we identified
the most commonly coded cancer sites on the death certificate. Among patients with a
primary diagnosis of melanoma of the skin, liver, or head and neck cancer, the most
frequently coded other cancer cause of death was miscellaneous malignant cancers (C26.1,
C45.7, C45.9, C76-C80, C88, C96.0-C96.2, C96.7, C96.9, C97), with 46%, 57%, and 61%,
respectively. Among patients diagnosed with melanoma of the skin, another 17% were
coded as lung and bronchus. An additional 15% of liver cancer patients were coded as
intrahepatic bile duct deaths. Head and neck cancer patients with another cancer cause of
death were attributed to skin, excluding basal or squamous cell, 13%, or lung or bronchus,
11%. Among gastric cancer patients, 59% were reported to be an esophageal cancer cause of
death with another 18% classified as miscellaneous malignant cancers. Nearly 53% of
uterine cancer patients were reported with another female gynecologic cancer cause of death
on the death certificate.
The percentage of patients with agreement between the initial diagnosis and site-specific
cause of death was lower for patients with multiple primaries. For these patients, the site-
specific cause of death agreed in 66–75% of patients with pancreatic, lung, breast, colorectal
cancers, and melanoma of the skin. Patients with prostate and head and neck cancers who
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had multiple primaries had the lowest reported site-specific cancer deaths, 39% and 36%,
respectively. However, the percentage of patients with multiple cancers who reportedly died
of cancer of any site was high at 90%.
Because of the challenges in attributing cancer deaths for patients with multiple cancers, we
restricted additional analyses to patients with only one primary cancer diagnosis. We
considered, by cancer site, whether the percentages of deaths attributable to site-specific
cancers, cancer cause-specific, or other causes differed by age, race/ethnicity, and sex. As
shown in Table 2, for all cancers, the percentage of patients dying from causes other than
cancer increased with age, and the trend was statistically significant for all cancer sites (p <.
05), except liver. For the vast majority of cancers, black and Hispanic patients were more
likely than white patients to have a reported cause of death other than cancer. The
percentage of deaths recorded on the death certificate as site-specific or any cancer cause of
death did not vary by sex, except for gastric cancer where women had a higher percentage of
site-specific cancer cause of death (data not shown).
We examined whether the cause of death on the death certificate varied with the length of
time from diagnosis to death (Table 3). For most cancers, percentages of reported site-
specific and cancer cause-specific deaths remained comparable across time. For colorectal,
lung, and prostate cancers, the percentages of patients with site-specific cancer causes of
death varied by time from diagnosis to death (p <.001), generally increasing through year
one and decreasing through years two and three. In ovarian cancer patients, the site-specific
percentage mono-tonically increased as time from diagnosis to death increased (p <.001).
DISCUSSION
Our analysis has shown that in a population of patients likely to die from cancer (i.e.,
patients diagnosed with distant stage disease), the percentage of deaths attributable to any
cancer as reported on the death certificate is high. The vast majority of patients (84%) were
reported as dying from the same site-specific cancer as diagnosed, and a smaller percentage
(8%) reportedly died of another cancer. We found that agreement on cause of death as coded
on the death certificate was higher for patients who had a single primary than for those with
multiple primaries.
In a prior study, medical records and SEER tumor registry data for prostate cancer patients
were used to evaluate the accuracy of New Mexico Bureau of Vital Statistics death
determinations for the years 1985 and 1995 (18). The study found high agreement in both
years between the New Mexico Bureau of Vital Statistics death determinations and the
medical record abstraction. Discordance between the New Mexico Bureau of Vital Statistics
and the medical abstract review was most common among patients with multiple primary
cancer diagnoses. Taken together, these findings suggest that studies using death certificates
to identify site-specific deaths should be restricted to patients with a single primary only.
The issue of multiple cancer primaries is of growing significance in the United States as the
number of cancer survivors has increased and the population is growing and aging (19). For
patients diagnosed with cancer at the age of 65 years and older from 1998 to 2003, 23% had
two or more primary cancers (17). Limiting the sample to patients with a single primary
cancer will result in reduced generaliz-ability, however, especially for studies of cancer in
the older age groups. Given the sizeable number of elderly cancer patients with multiple
primaries, researchers should perform sensitivity analyses to determine how the exclusion of
these patients would impact their findings.
For studies that include patients with only one primary cancer, the cause of death can be
limited to site-specific deaths only or expanded to include all cancer deaths. An earlier
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analysis of the cause of death found that physicians tended to report a nonspecific site of
cancer on the death certificate (1). The authors of the earlier analysis concluded that cancer
patients who have a single primary cancer diagnosis and an “other” cancer cause of death
reported on the death certificate are likely miscoded and that the cause of death for these
patients should be attributed to the specific cancer site. Our findings suggest that this
approach for patients with a single primary cancer diagnosis is reasonable.
Data from cancer registries, such as SEER, are often used to assess the effectiveness of
screening and treatment programs on survival. Accurate cause of death reporting is essential
for estimating site- and cancer-specific mortality and survival. A prior analysis of the
accuracy of cancer death certificates noted misclassification problems particularly for colon,
rectal, and uterine cancers (1). In our analysis of patients with a single primary advanced
colorectal cancer, agreement with the site-specific cause of death was 85%. However for
several sites, misclassification of the site-specific cause of death appeared greater. For
women with a single primary advanced stage uterine cancer, 18% had another cancer site
coded as the cause of death (of which nearly 53% were other gynecologic sites). Among
patients with melanoma of the skin or head and neck cancer, the other cancer causes of
deaths reported on the death certificate were frequently the nonspecific miscellaneous
malignant cancers. This suggests that the physician signing the death certificate may have
been uncertain of the site of origin of the cancer or unfamiliar with the patient’s medical
history; therefore, the physician used a more general cancer site code.
It is primarily the research, vital and health statistics, and health policy communities that are
interested in the specific details of cancer cause of death. The process of determining the
underlying cause of death reported on a death certificate requires a number of steps. First, a
certifying physician records multiple causes of death for a decedent and arranges them in a
sequence to reflect the etiologic relationship of the medical conditions that led to death.
Since the early 1970s, a software program, the Automated Classification of Medical Entities
(ACME), has been used as a primary method for determining cause of death by taking into
account the information on all medical conditions and their relationships to one another for
the reported death. The software selects from among all conditions reported by the physician
to determine the appropriate cause of death. The 10–15% of deaths that cannot be properly
classified using ACME are then manually adjudicated by a trained nosologist (20). This
process helps to ensure that causes of death reported on death certificates are as accurate as
possible. A recent study of lung cancer mortality by Doria-Rose et al. found that the cause
of death reported on the death certificates had an 89% sensitivity and 99% specificity
compared to the cause of death determined by a mortality review committee. Their analysis
reported that the use of the cause of death from the death certificate compared to the
mortality review board determination did not produce a meaningful change in mortality-
based outcomes (9).
Some researchers have used overall survival rather than cancer-specific survival for studies
of cancer patients (7, 8). Because overall survival includes deaths due to conditions other
than cancer, its use can be problematic. This is especially true among the elderly population,
which has the highest incidence of cancer. In our analysis, we observed that for 10 of 11
cancers, the portion of patients dying from conditions other than cancer increased with age.
In addition, we found that for many cancers, black and Hispanic patients were more likely
than white patients to die from conditions other than cancer. These findings underscore the
limitations of using all deaths, rather than cancer-specific deaths as a measure of treatment
or screening outcomes for cancer patients. It is important to note, however, that overall
mortality is a relevant endpoint to consider when assessing the effectiveness of cancer
therapies that may increase the risk of other noncancer adverse outcomes (e.g., heart failure)
and should be reported alongside cancer-specific mortality.
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The major strengths of this study include the large population-based sample, 10 years of
detailed data, and consistency of findings across cancer sites. However, our study also has
some limitations. To improve our ability to assess the cause of death on death certificates,
we restricted our analysis to cancer patients diagnosed with distant stage disease who died.
Therefore, we are unable to directly extrapolate our results to cancer patients diagnosed at
earlier stages. Yet, for many cancers, sizeable portions are diagnosed with distant stage
disease—51% for lung cancers and 67% for ovarian cancers (17). Lastly, we assumed that
patients diagnosed with distant stage cancer were likely to die from their diagnosed cancer.
However, we did not have access to medical record data to confirm this assumption.
An advantage of using the cause of death information obtained from the death certificate is
that the cost of acquiring these data is relatively low. Although the medical record may
provide more detailed information about the cause of death, the incremental expense and
time required to abstract medical records may be prohibitive for many studies. With growing
use of electronic health records, it may eventually be feasible to obtain cause of death
information from the medical record, although concerns about patient confidentiality may
limit access to them. In the absence of such data, our findings support the usefulness of the
cause of death reported on the death certificate to determine the cause-specific and site-
specific cause of death for most cancers reported for patients with single, distant stage |
primaries.
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